Compare Amphastar Pharmaceuticals Inc (AMPH) vs Global X Uranium ETF (URA) Price & Performance

AMPH trades at $19.98, down 1.62% today, with a bullish technical signal supported by moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.

The outlook is balanced with analyst consensus leaning Hold (66.67%) amid regulatory scrutiny and competitive pressures. Near-term catalysts include pipeline developments, but risks from FDA warnings and generic drug tariff uncertainties warrant caution. Cash flow trends improved with 2026 net cash flow projected at $36 million.

URA, the Global X Uranium ETF, trades at $45.20, up 1.85% on the day, with a bullish technical signal from moving averages and strong buying pressure indicated by ADX. The ETF benefits from positive sentiment around nuclear energy demand driven by AI power needs and government support, including a recent $17.5 billion U.S. loan commitment for new reactors. However, RSI levels suggest potential overbought conditions near-term.

The outlook for URA is positive due to structural tailwinds in nuclear energy, but risks include ETF expense ratios and uranium price volatility. Investor sentiment is bolstered by index expansions and geopolitical deals, yet the fund lacks traditional valuation metrics as it holds diversified uranium-related equities rather than operating as a single company.